MARATTO

article · Cureus

Peliosis Hepatis Presenting As Pseudometastatic Liver Lesions During Adjuvant Therapy for Colon Cancer: A Case Report

2026Open accessMohamed I University

Abstract

Peliosis hepatis (PH) is a rare benign vascular liver disorder that may closely mimic hepatic metastases on imaging, posing a significant diagnostic challenge in oncology. We report the case of a 54-year-old patient with left-sided nonmetastatic colon adenocarcinoma (pT4N0) treated surgically and receiving adjuvant Folinic acid, Fluorouracil, and Oxaliplatin chemotherapy for high-risk pathological features. During follow-up, contrast-enhanced computed tomography revealed a dysmorphic liver with a thin-walled lesion in segments II-III, highly suspicious for secondary hepatic involvement in the oncological context. A multidisciplinary decision led to a left hepatic lobectomy, and histopathological examination demonstrated PH, characterized by dilated congestive sinusoids and intraparenchymal hemorrhage, with preserved hepatic architecture and no evidence of malignancy or cirrhosis. Adjuvant chemotherapy was subsequently resumed and completed over a total of six months, with good tolerance. At the last follow-up, the patient showed no clinical, biological, or radiological evidence of disease recurrence. This case emphasizes the importance of including PH in the differential diagnosis of atypical hepatic lesions during oxaliplatin-based chemotherapy to avoid overstaging and unnecessary treatment modification.

Research topics

  • Bartonella species infections research
  • Amoebic Infections and Treatments
  • Infectious Disease Case Reports and Treatments

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.7759/cureus.105688

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.